10-K: Natural Alternatives International Reports Fiscal Year 2024 Results Amidst Sales Decline

Natural Alternatives International, Inc. (NAI) experienced a significant decrease in net sales and a net loss for fiscal year 2024, primarily due to reduced orders from key private-label contract manufacturing customers.

Summary

• Natural Alternatives International, Inc. (NAI) reported a 26% decrease in net sales for fiscal year 2024, totaling $113.8 million, compared to $154 million in the previous year.
• Private-label contract manufacturing sales declined by 27%, primarily due to reduced orders from major customers as they worked to reduce excess inventory.
• Patent and trademark licensing revenue decreased by 3% to $8.4 million, mainly due to increased volume rebates.
• The company experienced a net loss of $7.2 million for the fiscal year, compared to a net income of $2.5 million in the previous year.
• Gross profit decreased by 62% to $6.9 million, with a significant decline in the gross profit margin for private-label contract manufacturing.
• Selling, general, and administrative expenses increased by 15% to $15.4 million, due to the absence of non-recurring benefits recorded in the previous year.
• The company temporarily closed its high-speed powder processing facility in Carlsbad, California, due to reduced customer orders, but reopened it in May 2024.
• NAI anticipates a net loss in the first half of fiscal 2025, followed by net income in the second half, with a break-even or slight profit for the full year.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant sales decline, net loss, and operational challenges. While there are some positive aspects like new product development and certifications, the overall tone is pessimistic from an investment perspective.

Positives

• NAI reopened its high-speed powder processing facility in Carlsbad, California in May 2024, indicating a potential recovery in customer orders.
• The company continues to invest in research and development for its CarnoSyn product line, including the launch of TriBsyn, a new carnosine booster.
• NAI maintains a strong focus on quality and regulatory compliance, with certifications from TGA, NSF, Health Canada, and SSCI.
• The company has a diversified customer base, including companies in the direct sales, e-commerce, and retail channels.

Negatives

• The company experienced a significant decrease in net sales and a net loss for fiscal year 2024.
• Private-label contract manufacturing sales were significantly impacted by reduced orders from key customers.
• Gross profit and gross profit margin declined substantially, particularly in the private-label contract manufacturing segment.
• The temporary closure of the Carlsbad facility resulted in furloughs and operational disruptions.
• The company anticipates a net loss in the first half of fiscal 2025, indicating continued challenges in the near term.
• NAI is currently negotiating a potential revised line of credit due to anticipated non-compliance with existing covenants.

Risks

• The company is highly dependent on a limited number of customers, with the top three accounting for 68% of consolidated net sales in fiscal 2024.
• The loss of any major customer or a significant reduction in their orders could materially impact NAI's financial results.
• NAI relies on a single supplier for beta-alanine, a key raw material for its CarnoSyn products, creating a supply chain vulnerability.
• The company faces intense competition in the nutritional supplement industry, which could lead to price reductions and reduced market share.
• NAI's operations are subject to various regulatory risks, including compliance with GMPs and other regulations in the U.S. and abroad.
• The company is exposed to risks related to global economic instability, including supply chain issues, inflation, and geopolitical tensions.
• NAI may face product liability claims or other litigation, which could be costly and adversely affect its operations.
• The company may not be able to raise additional capital or obtain additional financing if needed, which could hinder its growth and operations.

Future Outlook

NAI anticipates a net loss in the first half of fiscal 2025, followed by net income in the second half, with a break-even or slight profit for the full fiscal year. The company plans to focus on leveraging its facilities, expanding its beta-alanine patent estate, and improving operational efficiencies.

Management Comments

• Management is monitoring the conflict in Ukraine and any broader economic effects from the crisis.
• Management is monitoring the conflict in Israel and Gaza and any broader economic effects from the crisis.
• Management believes there is an opportunity to enhance consumer confidence in the quality of nutritional supplements through education provided by direct sales and direct-to-consumer marketing programs.
• Management believes SR CarnoSyn and TriBsyn are superior delivery systems for CarnoSyn beta-alanine.
• Management believes its comprehensive approach to customer service is unique within the industry.

Industry Context

The nutritional supplement industry is highly competitive and fragmented, with sales occurring through various channels including retail, e-commerce, and direct sales. NAI competes with other manufacturers, distributors, and marketers of vitamins, minerals, and other nutritional supplements. The company's performance is influenced by consumer demand, economic conditions, and regulatory changes.

Comparison to Industry Standards

• The document does not provide specific details on the performance of comparable companies.
• However, the document does state that the nutritional supplement industry is highly competitive and fragmented.
• The document does not provide specific details on the performance of comparable projects.
• The document does not provide specific details on the performance of comparable results.

Stakeholder Impact

• Shareholders will be negatively impacted by the net loss and decreased sales.
• Employees experienced furloughs due to the temporary closure of the Carlsbad facility.
• Customers may be affected by supply chain disruptions and potential changes in product availability.
• Suppliers may be impacted by changes in NAI's purchasing patterns and potential shifts in sourcing.

Next Steps

• NAI plans to continue its sales and marketing activities to promote CarnoSyn, SR CarnoSyn, and TriBsyn beta-alanine products.
• The company will focus on leveraging its state-of-the-art facilities to increase the value of its services.
• NAI will continue to expand the commercialization of its beta-alanine patent estate.
• The company will work to improve operational efficiencies and manage costs to improve profitability.
• NAI is currently negotiating a potential revised line of credit.

Key Dates

Keywords

contract manufacturing, nutritional supplements, beta-alanine, CarnoSyn, SR CarnoSyn, TriBsyn, private label, patent licensing, GMP, supply chain, financial results, net sales, profitability, manufacturing, research and development